List of Truseltiq drug patents
Truseltiq is owned by Helsinn Hlthcare.
Truseltiq contains Infigratinib Phosphate.
Truseltiq has a total of 4 drug patents out of which 0 drug patents have expired.
Truseltiq was authorised for market use on 28 May, 2021.
Truseltiq is available in capsule;oral dosage forms.
Drug patent challenges can be filed against Truseltiq from 2025-05-28.
The generics of Truseltiq are possible to be released after 11 December, 2034.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9067896 | HELSINN HLTHCARE | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl) -phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof |
Aug, 2028
(5 years from now) | |
| US8552002 | HELSINN HLTHCARE | Compounds and compositions as protein kinase inhibitors |
Aug, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10278969 | HELSINN HLTHCARE | Pharmaceutical dosage forms |
Dec, 2034
(11 years from now) | |
| US11160804 | HELSINN HLTHCARE | Pharmaceutical dosage forms |
Dec, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 28, 2026 |
| Orphan Drug Exclusivity (ODE) | May 28, 2028 |
Drugs and Companies using INFIGRATINIB PHOSPHATE ingredient
NCE-1 date: 2025-05-28
Market Authorisation Date: 28 May, 2021
Treatment: NA
Dosage: CAPSULE;ORAL
TRUSELTIQ family patents
14
United States
9
China
7
European Union
6
Peru
6
New Zealand
5
Japan
4
Australia
4
Argentina
4
Spain
4
Taiwan, Province of China
3
South Africa
3
Denmark
3
Mexico
3
Hong Kong
3
Slovenia
3
Morocco
3
Singapore
3
Croatia
3
Malaysia
3
Korea, Republic of
3
Poland
3
Ecuador
3
Canada
3
Tunisia
2
Israel
2
Russia
2
Hungary
2
Philippines
2
Brazil
2
Portugal
2
Cyprus
2
Chile
1
IB
1
Austria
1
Jordan
1
Lithuania
1
Norway
1
Guatemala
1
United Kingdom
1
RS
1
EA
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic